Larysa Kuts

Larysa Kuts

Auto-generated profile, based on publicly available information

Larysa Kuts

Sumy State University, Sumy, Ukraine

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 May 2025 in Ukrainian Journal of Nephrology and Dialysis
Verified
Journal Article
Open access
PDF file
NDNadiia Demikhova
Nadiia Demikhova
LKLarysa Kuts
Larysa Kuts
SBSvitlana Bokova
Svitlana Bokova
EMEda Merisalu
Eda Merisalu
OVOlga Vlasenko
Olga Vlasenko
Interleukin-37 (IL-37) is a newly discovered anti-inflammatory cytokine from the IL-1 family that plays a key role in regulating both innate and adaptive immune responses. It is secreted in healthy tissues, reflecting a homeostatic function. Intracellularly, IL-37 suppresses diverse inflammatory signals in various cells, including dendritic cells, macrophages, epithelial cells, and endothelial cells. Although it has been studied in many conditions, such as autoimmune disorders, cancer, and cardiovascular disease, its specific role in kidney diseases remains relatively understudied. In this mini-review, we summarize current evidence on the biology of IL-37, with a focus on its relevance to kidney disease. We explore its molecular structure, patterns of expression, and the immunomodulatory mechanisms that may influence kidney diseases, including acute kidney injury, diabetic nephropathy, and autosomal dominant polycystic kidney disease. We also discuss the challenges of translating IL-37-based therapies into clinical practice and highlight key areas for future research aimed at unlocking its potential in the treatment of kidney diseases.

24 February 2026 in Ukrainian Journal of Nephrology and Dialysis
Verified
Journal Article
Open access
PDF file
MCMariia Cherska
Mariia Cherska
OPOlena Pavlenko
Olena Pavlenko
VZVira Zlatkina
Vira Zlatkina
LKLarysa Kuts
Larysa Kuts
KTKarina Taraniuk
Karina Taraniuk
Yusuf Ziya ŞenerYusuf Ziya Şener
Yusuf Ziya Şener
Dyslipidemia is a characteristic feature of nephrotic syndrome (NS), which significantly increases the risk of cardiovascular complications and progression of chronic kidney disease. This review analyzes current understanding of the complex pathophysiological mechanisms of lipid metabolism disorders in NS. Particular attention is paid to the impact of proteinuria on the synthesis of lipoproteins by the liver and impaired clearance. The article systematizes current therapeutic strategies. Therapeutic prospects aimed at correcting the lipid profile as a means of nephroprotection are considered. The review emphasizes the need for a personalized approach to the management of dyslipidemia, taking into account the etiology of NS and the functional state of the kidneys.